Roche sets the gantenerumab expectations
Graduate 1 and 2 data are “not yet in house”, but a pooled analysis beckons in the event of one study failing.
FDA scrutiny now hits Parp inhibitors
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Go or no go? GSK takes its turn with a novel anaemia class
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Prometheus takes on Pfizer in inflammatory bowel diseases
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
